NTRA   $174.0  2.86% Market Closed After Close 175.04 0.60%

Natera Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-06 Trend pattern changed from сужающийся канал to канал.

2023-08-06 Signal in Stochastic changed from bearish recovery to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: main and signal line crossing.

2023-08-06 Signal in MACD changed from bearish recovery to bullish reversal. Oscillator MACD is in the negative territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the end of the downward trend. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish recovery to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in EMA100 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.


Current temperature: 9.80
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 18
Target Price Mean 174.06
Mean unverified/preliminary 174.06 / 174.06
Target Price Low / High 157.00 / 209.00
Median / STD DEV 175.00 / 14.81
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy Sell
rsi Buy Sell Sell
macd None None None
stoch None None None
ma20 Sell Sell Sell
ma50 None None None
ma100 Buy Buy Sell
Candlestick PatternNov. 15, 2024 Bearish Three Outside Down - pattern is a made up of three candlesticks. A white candlestick appears on the first day in a uptrend. The second day body engulfs the white body of the first day. A black candlestick on the third day with a lower close than the second day. Considered to be a bearish reversal pattern.
ISIN US6323071042
ceo Mr. Steven Leonard Chapman
Website https://www.natera.com
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.